The DOI matches its Crossref record; 96 of the 96 references it cites were found in a registry or an index; 74 of the 161 sources its claims cite were checked for support.
Etiology-Based Treatment for Unresectable/Advanced Hepatocellular Carcinoma: Focus on Viral Hepatitis and Metabolic Dysfunction-Associated Steatohepatitis
Open accessAbstract
Background: Immune checkpoint inhibitors (ICI) are a keystone in advanced hepatocellular carcinoma (aHCC) therapy. However, preclinical evidence suggests that mice with pure metabolic dysfunction-associated steatohepatitis (MASH)-related HCCs may not benefit from ICIs. This has tremendous implications for both therapy selection and future drug development. Summary: Viral and MASH-HCCs differ in molecular pathogenesis and immune microenvironment. Preclinical evidence has shown impaired immune surveillance and ICI-induced auto-aggressive T cells in pure MASH-HCC. Phase 3 clinical trials and meta-analyses have conflicting outcomes. For single-ICI regimens with anti-programmed-death 1/L1 (anti-PD1/L1), there was no apparent difference in the overall survival for patients with non-viral HCCs in the CheckMate-459, IMbrave150, COSMIC-312, and KEYNOTE-240 trials for ICI over tyrosine-kinase inhibitors or placebo, while patients with viral hepatitis seemed to have benefited more. Meanwhile, comparable outcomes were seen for patients with viral and non-viral HCCs in the HIMALAYA, RATIONALE-301, LEAP-002, and CARES-310 trials. There was no consistent difference in outcomes between patients with HBV or HCV-HCCs. For dual-ICI regimens with anti-PD1/L1 and anti-cytotoxic T-lymphocyte associated protein-4 (anti-CTLA-4), the HIMALAYA and CheckMate-9DW trials showed similar efficacy for ICI combinations across all etiologies. Important caveats in interpreting current evidence exist. All trial data are from unplanned subgroup analyses only, limiting the level of clinical evidence available. "Non-viral HCCs" are also a heterogenous entity, the composition of which varies from trial to trial. Fundamentally, defining HCC etiologies, especially in mutually exclusive terms, is challenging: Occult hepatitis B infections are inconsistently tested and reported; hence, viral HCCs may be underreported. HCCs are often multifactorial, with steatosis frequently co-existing and interacting with viral hepatitis, creating difficulty in translating findings from pure MASH-HCC mouse models. Key Messages: Current evidence is insufficient to support individualizing aHCC treatment based on etiology. Preclinical evidence for a lesser benefit with ICIs in MASH-HCCs exists, while data from clinical trials are mixed but limited. Major gaps in knowledge remain, and further studies are required to clarify this important subject.
Overview
CoChat Summary
## TL;DR
This narrative review concludes that current evidence is insufficient to support tailoring unresectable/advanced HCC treatment by etiology, even though preclinical studies suggest ICIs may be less effective or potentially harmful in pure MASH-HCC. Across phase 3 trials and meta-analyses, results are mixed, with more consistent benefit for viral HCCs in some single-ICI studies and preserved efficacy of dual-ICI regimens across etiologies.
## Key findings
- Preclinical studies in NASH/MASH models found that anti-PD1 therapy could worsen NASH and increase HCC incidence, and that mice with pure MASH-HCC may not benefit from ICIs.
- In CheckMate-459, OS HRs for nivolumab vs sorafenib were 0.77 for HBV-HCC, 0.71 for HCV-HCC, and 0.95 for non-viral HCC; ORRs were 19%, 17%, and 12%, respectively, versus 7–8% with sorafenib.
- In KEYNOTE-240, pembrolizumab vs placebo showed a numerically greater OS benefit in HBV-HCC (HR 0.57) than in non-viral HCC (HR 0.88); the authors note only 15.5% of patients had HCV-HCC.
- Meta-analyses were inconsistent: one pooled analysis of 3 ICI trials (n = 1,656) found better OS in viral than non-viral HCCs (HR 0.64 vs 0.92, p for heterogeneity = 0.0259), while a later meta-analysis found OS benefit in both viral and non-viral HCCs (HR 0.79 overall; HBV 0.70, HCV 0.78, non-viral 0.87).
## Methods
- Narrative review of preclinical, translational, and clinical literature on ICI use in HCC across etiologies, focusing on viral hepatitis and MASH-related HCC.
- Literature searches were conducted in electronic databases such as PubMed, restricted to English-language publications, with additional citation chasing from retrieved papers.
- The paper synthesizes phase 3 trial subgroup analyses and meta-analyses; no primary patient-level dataset or original statistical analysis was performed by the authors.
## Limitations
- The paper states that most clinical evidence comes from unplanned subgroup analyses that are not powered for formal comparison, and meta-analyses are based on trial-level rather than individual patient data.
- The paper states that etiology definitions are inconsistent across trials, including variable testing for occult HBV and lack of biopsy-based confirmation of MASH; “non-viral” groups are heterogeneous.
- Evident from the text: the review’s clinical conclusions are constrained by incomplete reporting of baseline characteristics, toxicities, ORR/DCR, survival curves, and post-progression therapy by etiology, so findings remain hypothesis-generating rather than definitive.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
28 Valid · 31 Not valid · 65 Not checked · 60 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“However, in a more recent meta-analysis conducted by Meyer et al. [48] which included other studies mentioned above, a significant OS advantage for both patients with viral and non-viral HCCs was found (HR 0.79, p < 0.001).”
§ Etiology-Based Treatment for Unresectable/Advanced Hepatocellular Carcinoma: Focus on Viral Hepatitis and Metabolic Dysfunction-Associated Steatohepatitis > Clinical Evidence: A Critical Appraisal > Summary of Current Evidence
What the sources say
- Disputedcites [48] sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) says this meta-analysis used only objective response rate because too few studies reported overall survival (OS) by viral status. Its Results report an ORR comparison, not the claimed significant OS advantage or HR 0.79. The paper therefore explicitly rules out the OS meta-analysis attributed to it. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Patients with HBV-HCCs had the largest predicted benefit (HR 0.70, p < 0.001), followed by patients with HCV-HCCs (HR 0.78, p = 0.04) and patients with non-viral HCCs (HR 0.87, p = 0.02).”
§ Etiology-Based Treatment for Unresectable/Advanced Hepatocellular Carcinoma: Focus on Viral Hepatitis and Metabolic Dysfunction-Associated Steatohepatitis > Clinical Evidence: A Critical Appraisal > Summary of Current Evidence
What the sources say
- Disputedcites [48] sourceExperimental — accuracy not yet measured
The Results section reports odds ratios for objective response rate, not the claimed HCV-HCC hazard ratio of 0.78 (p = 0.04). The Discussion states that objective response rate was the only reliable endpoint for this meta-analysis because too few studies reported survival outcomes by viral etiology. Page numbers are unavailable in our copy. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“Further stratification of non-viral etiologies was only done in COSMIC-312 and LEAP-002”
§ Etiology-Based Treatment for Unresectable/Advanced Hepatocellular Carcinoma: Focus on Viral Hepatitis and Metabolic Dysfunction-Associated Steatohepatitis > Major Limitations in Available Clinical Evidence
What the sources say
- Partly supportedcites [35] sourceExperimental — accuracy not yet measured
The Methods passage (page not available in our copy) says COSMIC-312 randomisation was stratified by disease aetiology. It does not establish further stratification within non-viral aetiologies or the claim that only COSMIC-312 and LEAP-002 did this; searches for “non-viral” and LEAP-002 found no supporting passage. (LLM, conf=0.72)
- Disputedcites [36] sourceExperimental — accuracy not yet measured
The Statistical Analysis section (page unavailable) lists viral aetiology as a yes-or-no subgroup but does not subdivide non-viral aetiologies; it also says that no additional subgroups were included post hoc. That is contrary to the claim that LEAP-002 further stratified non-viral aetiologies. This paper does not establish which other trials did so. (LLM, conf=0.78)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“preclinical evidence suggests that mice with pure metabolic dysfunction-associated steatohepatitis (MASH)-related HCCs may not benefit from ICIs.”
- Also stated in: § Molecular and Microenvironment Differences of Viral and MASH-Related HCCs · plain
“Finally, when mice with NASH-HCC were given anti-PD1, no response was obtained despite expanded CD8+PD1+CXCR6+, TOX+, and TNF+ T cells [22].”
§ Etiology-Based Treatment for Unresectable/Advanced Hepatocellular Carcinoma: Focus on Viral Hepatitis and Metabolic Dysfunction-Associated Steatohepatitis > Abstract > Background
What the sources say
- Supportedcites [22] source
In “Hepatic CD8+PD1+ T cells increase in NASH,” mice with diet-induced NASH–HCC showed no regression of existing tumours after anti-PD1 or anti-PDL1 treatment. The paper contrasts this with tumour regression in non-NASH mouse models, supporting the qualified claim that mice with MASH-related HCC may not benefit from ICIs. (LLM, conf=0.91)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Molecular and Microenvironment Differences of Viral and MASH-Related HCCs · plain
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“In RATIONALE-301, the HR for patients with HBV, HCV, and non-viral HCCs were 0.91 (0.73–1.14), 0.64 (0.38–1.08), and 0.78 (0.55–1.12) in the tislelizumab arm [29].”
§ Etiology-Based Treatment for Unresectable/Advanced Hepatocellular Carcinoma: Focus on Viral Hepatitis and Metabolic Dysfunction-Associated Steatohepatitis > Clinical Evidence: A Critical Appraisal > Summary of Current Evidence
What the sources say
- Could not verifycites [29] sourceExperimental — accuracy not yet measured
The Methods (Statistical Analysis; page unavailable) identify HCV etiology as an analysis factor, and the Discussion (page unavailable) mentions OS subgroup analyses. Searches for the HCV subgroup HR and its reported confidence interval found neither 0.64 nor 0.38–1.08 in our copy, so the specific estimate cannot be verified. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
137 more claims · 40 with their cited sources checked
Create a free account to see all 184 claims and to verify the 29 references still open.
- It may state two separate claims as one. 31
- Probably not a substantial claim. 13
Citations
Cites
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
Finn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Kudo, M., Breder, V., Merle, P., Kaseb, A. O., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915745 · Cited by 7,470 · cited 2×
“As an example, the proportion of patients classified to have non-viral HCC ranged from less than 20% in CARES-310, 30.5% in IM-Brave150 to up to 45% in Checkmate-459 [27, 37, 62].”
InfluentialLlovet, J. M., Kelley, R. K., Villanueva, A., Singal, A. G., Pikarsky, E., Roayaie, S., Lencioni, R., Koike, K., Zucman-Rossi, J., & Finn, R. S. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00240-3 · Cited by 7,055
Kudo, M., Finn, R. S., Qin, S., Han, K.-H., Ikeda, K., Piscaglia, F., Baron, A., Park, J.-W., Han, G., Jassem, J., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30207-1 · Cited by 5,497 · cited 2×
“Only IMBrave150 and COSMIC-312 re-ported the median OS in patients with non-viral HCCs [31, 35], but the outcomes for sorafenib were remarkable (18 and 20 months) compared to patients with viral HCCs in the same trials (12–14 months) or to historical data of sorafenib in unselected HCC [32, 33].”
InfluentialMechanisms of NAFLD development and therapeutic strategies
Friedman, S. L., Neuschwander-Tetri, B. A., Rinella, M., & Sanyal, A. J. (2018) · Nature Medicine · doi:10.1038/s41591-018-0104-9 · Cited by 4,354 · cited 1×
“MASH promotes HCC through lipotoxicity, causing oxidative and endoplasmic reticulum stress, which induces inflammation and cell damage [14, 15] reactivation of molecular pathways such as Notch, Hedgehog, and YAP-TAZ in hepatocytes leads to inflammation, cell proliferation, and cancer [16].”
The Global Epidemic of the Metabolic Syndrome
Saklayen, M. G. (2018) · Current Hypertension Reports · doi:10.1007/s11906-018-0812-z · Cited by 3,990 · cited 1×
“The global epidemic of metabolic syndrome has contributed significantly to the increasing prevalence of MAFLD [6] which has increased over 50% in the Asia-Pacific region over the past two decades and affects 30–40% of the global population [3, 4, 7].”
Younossi, Z. M., Golabi, P., Paik, J. M., Henry, A., Van Dongen, C., & Henry, L. (2023) · Hepatology · doi:10.1097/hep.0000000000000004 · Cited by 3,383 · cited 1×
“1), the “non-viral” subgroups probably consist of different proportions of HCCs due to each etiology across different trials, as the above example has shown [63–65].”
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
Rinella, M. E., Lazarus, J. V., Ratziu, V., Francque, S. M., Sanyal, A. J., Kanwal, F., Romero, D., Abdelmalek, M. F., Anstee, Q. M., Arab, J. P., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.06.003 · Cited by 3,100 · cited 1×
“…dysfunction-associated steatotic liver disease (MASLD), defined as hepatic steatosis in the setting of at least one cardiometabolic risk factor without other causes of steatosis, can progress to MASH, characterized by histological features of lobular inflammation and hepatocellular ballooning [5].”
Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma
Ally, A., Balasundaram, M., Carlsen, R., Chuah, E., Clarke, A., Dhalla, N., Holt, R. A., Jones, S. J. M., Lee, D., Ma, Y., et al. (2017) · Cell · doi:10.1016/j.cell.2017.05.046 · Cited by 2,490 · cited 2×
“HCV-HCCs demonstrate increased TERT promoter mutation and CDKN2A promotor silencing, which leads to downregulation of tumor suppressor p16 [12].”
Estes, C., Razavi, H., Loomba, R., Younossi, Z., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29466 · Cited by 2,399
Cited by
HBV Integration in Clinical Management of Hepatocellular Carcinoma by Liquid Biopsy
Lyu, X., Chan, Z., & Ho, D. W.-H. (2026) · Oncology · doi:10.1159/000551214
“Notably, HBV-associated HCC patients had a better outcome of immune checkpoint inhibitor therapy [112, 113].”
Light across the Pacific Ocean: An Asian perspective on BEACON-HCC
Yau, T. W. C., Yuen, M.-F., & Cheung, T.-T. (2026) · Hepatology · doi:10.1097/hep.0000000000001857
Self-citation
Metadata
- Authors
- Sun, F. S. K., Wong, J. S. L., Mak, L.-Y., Wong, C. C.-L., Chew, V., Li, B. C. W., Leung, R., Cheung, T. T., & Yau, T.
- Affiliations
- Queen Mary Hospital (CN)
- University of Hong Kong (HK)
- SingHealth (SG)
- Corresponding author
- Yau, Thomas
- Venue
- Liver Cancer
- Publisher
- S. Karger AG
- Published
- 2025-09-19
- Volume
- 15
- Issue
- 3
- Pages
- 480-496
- ISSN
- 1664-5553 (ISSN-L)
- 2235-1795
- PMC
- PMC13286557
- OpenAlex
- W7082294778
- Semantic Scholar
- 627873f4f828a9e83ea081d33a6db7d96b6b7fde
- Cited by
- 3
- References
- 96
- Citations by year
- 2026: 3
- FWCI
- 0.29
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- creativecommons.org/licenses/by-nc/4.0/ (vor)
- creativecommons.org/licenses/by-nc/4.0/ (tdm)
- Locations
- Liver Cancer (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Epidemiology › Hepatitis B Virus Studies
- Keywords
- advanced hepatocellular carcinoma, immune checkpoint inhibitors, nonalcoholic steatohepatitis, viral hepatitis, hepatitis B, hepatitis C, cancer etiology, PD-1/PD-L1 blockade, CTLA-4 blockade, immune microenvironment, immune surveillance, subgroup analysis, tyrosine kinase inhibitors, steatosis, treatment selection
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Etiology-Based Treatment for Unresectable/Advanced Hepatocellular Carcinoma: Focus on Viral Hepatitis and Metabolic Dysfunction-Associated Steatohepatitis. https://app.cochat.ai/papers/10.1159/000548536
- The paper
- Sun, F. S. K., Wong, J. S. L., Mak, L.-Y., Wong, C. C.-L., Chew, V., Li, B. C. W., Leung, R., Cheung, T. T., & Yau, T. (2025). Etiology-Based Treatment for Unresectable/Advanced Hepatocellular Carcinoma: Focus on Viral Hepatitis and Metabolic Dysfunction-Associated Steatohepatitis. Liver Cancer. https://doi.org/10.1159/000548536
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.